Table 3.
Eradication rates of modified quadruple therapy and bismuth-containing quadruple therapy in the presence of antibiotic resistance.
| Per-protocol population | PAMB | PBMT | p value |
|---|---|---|---|
| Amoxicillin resistance | 83.3% (5/6) | 83.3% (5/6) | >0.99 |
| Metronidazole resistance | 100% (26/26) | 97% (32/33) | >0.99 |
| Tetracycline resistance | 100% (7/7) | 100% (5/5) | >0.99 |
| Clarithromycin resistance* | 96.2% (25/26) | 95.8% (23/24) | >0.99 |
| Levofloxacin resistance | 97.2% (35/36) | 96.3% (26/27) | >0.99 |
| Ciprofloxacin resistance | 100% (32/32) | 93.8% (30/32) | 0.49 |
| Dual clarithromycin & metronidazole resistance | 100% (6/6) | 100% (4/4) | >0.99 |
*Sequencing-based results.